Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Episodic Migraine Clear all
Completed Phase 3 Interventional Results available

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

NCT03939312
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
113
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Sep 17, 2026, 4:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Molecular and Functional PET-fMRI Measures of Analgesia in Migraine

NCT01970943
View directory record Official record
Conditions
Migraine, Healthy
Interventions
Placebo
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Sep 17, 2026, 4:17 AM EDT
Not listed No phase listed Observational

The Effect of Daylight Saving Time Transitions on Sleep and Migraine Headaches.

NCT05742191
View directory record Official record
Conditions
Episodic Migraine
Interventions
Daylight Savings time transitions
Other
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Sep 17, 2026, 4:17 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

NCT03238781
View directory record Official record
Conditions
Chronic Migraine or Episodic Migraine
Interventions
Placebo, AMG 301
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Long Beach, California • Santa Monica, California • Boulder, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Sep 17, 2026, 4:17 AM EDT
Completed Phase 1 Interventional

Safety, Efficacy and Pharmacokinetics of ALD403

NCT01772524
View directory record Official record
Conditions
Migraine
Interventions
ALD403, Placebo
Biological · Drug
Lead sponsor
Alder Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Phoenix, Arizona • Anaheim, California • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Sep 17, 2026, 4:17 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Tolerability, and Safety Study of DFN-15

NCT03006276
View directory record Official record
Conditions
Migraine Headache
Interventions
DFN-15 Active, DFN-15 Placebo
Drug · Other
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 75 Years
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Sep 17, 2026, 4:17 AM EDT
Not yet recruiting Not applicable Interventional

Behavioral Resources and Awareness for Veterans With Episodic Migraine: Impact on Neurological Disability and Quality of Life- Pilot

NCT07792291
View directory record Official record
Conditions
Migraine, Migraine Headache, Episodic Migraine Headache
Interventions
Cognitive behavioral therapy for migraine (CBTm), MEintervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
West Haven, Connecticut • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 17, 2026, 4:17 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

NCT06625060
View directory record Official record
Conditions
Episodic Migraine, Chronic Migraine
Interventions
Corabotase, Placebo, Corabotase dose A, Corabotase dose B
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
68
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 17, 2026, 4:17 AM EDT
Completed No phase listed Observational Results available

Prevalence of Phonophobia and Cutaneous Allodynia in Episodic Migraineurs

NCT00386880
View directory record Official record
Conditions
Migraine
Interventions
Sounds
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Sep 17, 2026, 4:17 AM EDT
Completed Phase 3 Interventional

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

NCT04686136
View directory record Official record
Conditions
Episodic Migraine, Chronic Migraine
Interventions
Atogepant 60 mg
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
42
States / cities
Phoenix, Arizona • Fresno, California • Los Alamitos, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 17, 2026, 4:17 AM EDT
Recruiting Not applicable Interventional

Chiropractic Care for Episodic Migraine

NCT06229834
View directory record Official record
Conditions
Episodic Migraine
Interventions
Chiropractic Care, Headache Health Education
Procedure · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 17, 2026, 4:17 AM EDT
Terminated No phase listed Observational

Predicting Migraine Attacks Based on Environmental and Behavioral Changes as Detected From the Smartphone

NCT03762902
View directory record Official record
Conditions
Migraine Disorders, Headache Disorders, Headache Disorders, Primary, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases
Interventions
Not listed
Lead sponsor
Lifegraph Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Detroit, Michigan • West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Sep 17, 2026, 4:17 AM EDT
Completed Phase 2 Interventional Results available

Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine

NCT02176018
View directory record Official record
Conditions
Episodic Migraine
Interventions
Dextromethorphan and quinidine, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Rockford, Illinois • Ridgeland, Mississippi • City of Saint Peters, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Sep 17, 2026, 4:17 AM EDT
Completed Phase 3 Interventional Results available

Occipital Blocks for Acute Migraine

NCT03526874
View directory record Official record
Conditions
Chronic Migraine, Headache, Episodic Migraine
Interventions
Lidocaine 4% Topical Application Cream [LMX 4], Lidocaine Hydrochloride 2 mg/mL Injectable Solution, Normal Saline
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
7 Years to 21 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Sep 17, 2026, 4:17 AM EDT
Completed Not applicable Interventional Results available

A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache

NCT01899040
View directory record Official record
Conditions
Migraine Headache, Episodic
Interventions
neuromodulation for episodic migraine headache
Device
Lead sponsor
Scion NeuroStim
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
San Diego, California • Ann Arbor, Michigan • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Sep 17, 2026, 4:17 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

NCT04530110
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
32
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Jacksonville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 17, 2026, 4:17 AM EDT
Completed Not applicable Interventional Results available

Electrical Stimulation of the Sphenopalatine Ganglion for the Treatment of Migraine Headaches

NCT01294046
View directory record Official record
Conditions
Migraine Headache
Interventions
Deep Brain Stimulation of SPG for Migraine
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Sep 17, 2026, 4:17 AM EDT
Completed Phase 3 Interventional Results available

Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

NCT04740827
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant 60 mg, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
26
States / cities
Colton, California • Encino, California • Los Alamitos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 17, 2026, 4:17 AM EDT
Completed Phase 4 Interventional Results available

Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

NCT05207865
View directory record Official record
Conditions
Migraine, Episodic Migraine, Phonophobia, Photophobia
Interventions
Rimegepant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
19
States / cities
Phoenix, Arizona • Hawthorne, California • North Hollywood, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Sep 17, 2026, 4:17 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Aspirin Resistance in Women With Migraine

NCT01257893
View directory record Official record
Conditions
Episodic Migraine, Chronic Migraine
Interventions
Aspirin (acetylsalicylic acid), Placebo
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Sep 17, 2026, 4:17 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

NCT06602479
View directory record Official record
Conditions
Migraine
Interventions
MEDI0618, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 70 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Huntsville, Alabama • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 17, 2026, 4:17 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine

NCT03912337
View directory record Official record
Conditions
Migraine
Interventions
Placebo, Erenumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
28
States / cities
Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Sep 17, 2026, 4:17 AM EDT
Terminated Not applicable Interventional Results available

A Research Study Examining the Use of Olanzapine for the Prevention of Migraine

NCT00203307
View directory record Official record
Conditions
Migraine
Interventions
Olanzapine during first intervention period and placebo during second intervention period, Placebo during first intervention period, then olanzapine during second intervention period
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Sep 17, 2026, 4:17 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

NCT03836040
View directory record Official record
Conditions
Migraine
Interventions
Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
38
States / cities
San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 17, 2026, 4:17 AM EDT